ArticleCancer management and research2026
Factors Influencing Survival After Curative Gastrectomy in Oligometastatic Gastric Cancer: A Single-Center Study.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer remains a major global health burden. Oligometastatic gastric cancer (OMGC) represents an intermediate disease state with limited metastatic spread and potential eligibility for multimodal treatment. Objective: To evaluate clinicopathological factors associated with overall survival (OS) and progression-free survival (PFS) in patients undergoing curative-intent surgery for OMGC. Methods: This retrospective study included 38 patients with de novo OMGC who underwent curative-intent gastrectomy between 2011 and 2023. Oligometastatic disease was defined according to OMEC/Bertinoro 2024 criteria: solitary liver metastasis (Group A), para-aortic lymph node metastasis (Group B), or limited peritoneal dissemination (Group C, PCI ≤6). Survival was analyzed using Kaplan-Meier and Cox regression. Results: Median follow-up was 28 months; 32 patients (84.2%) died. Median OS was 18.0 months. Female sex and age ≥65 years were associated with longer OS (p=0.003 and p=0.001). Adjuvant chemotherapy (HR=0.24; p<0.001) and adjuvant chemoradiotherapy (p=0.039) improved OS. R0 resection rates varied: liver 85.7%, para-aortic 62.5%, peritoneal 12.5%. Five-year OS was 41% for liver metastases vs 0% for peritoneal disease. Harvest of ≥30 lymph nodes was independently associated with improved OS (HR=0.45; p=0.028). Conclusion: Survival in OMGC is strongly influenced by metastatic pattern, adequacy of lymphadenectomy, and adjuvant therapy. Liver metastases have the most favorable prognosis; peritoneal involvement requires highly selective criteria for surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.